Literature DB >> 24975344

Prevalence of sleep disorders in patients with neurofibromatosis type 1.

A I Maraña Pérez1, A Duat Rodríguez2, V Soto Insuga3, J Domínguez Carral2, V Puertas Martín2, L González Gutiérrez Solana2.   

Abstract

INTRODUCTION: Neurofibromatosis type 1 (NF1) is frequently associated with neurological disorders unrelated to neurofibromas, including sleep disorders.
OBJECTIVES: This article reviews the prevalence of sleep disorders in patients with NF1, compares rates to data reported in the literature, and analyses the relationship between cognitive disorder and attention deficit hyperactivity disorder (ADHD) in these patients.
MATERIAL AND METHODS: Comparative retrospective study reviewing data collected between January 2010 and January 2012 from patients diagnosed with NF1 in a tertiary hospital.
RESULTS: We included 95 paediatric patients with NF1 who completed the Bruni Sleep Disturbance Scale in Children. The overall prevalence of sleep disorders was 6.3%, which was lower than in the general paediatric population. Patients with NF1 and ADHD had a higher prevalence of sleep onset and maintenance disorders (18% vs 6.3%), sleep-wake transition disorders (12.5% vs 6.3%), and daytime sleepiness (12.5% vs 7.9%); differences were not statistically significant. A statistically significant difference was found in the subdomain of nocturnal hyperhidrosis (21.9% vs 6.3%, P < 0.05). Patients with NF1 and IQ<85 showed higher prevalence rates of daytime sleepiness (20% vs 6.7%) and of sleep hyperhidrosis (11% vs 0%).
CONCLUSIONS: The prevalence of sleep disorders in our cohort of patients with NF1 was no higher than in the general paediatric population, although some of these disorders are more common in cases with cognitive disorders or ADHD.
Copyright © 2013 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Attention deficit hyperactivity disorder; Hiperhidrosis; Hyperhidrosis; Neurofibromatosis; Sleep; Sleep-wake; Sleepiness; Somnolencia; Sueño; Sueño-vigilia; Trastorno por déficit de atención e hiperactividad

Mesh:

Year:  2014        PMID: 24975344     DOI: 10.1016/j.nrl.2014.04.015

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  3 in total

1.  Assessment of nociception and related quality-of-life measures in a porcine model of neurofibromatosis type 1.

Authors:  Rajesh Khanna; Aubin Moutal; Katherine A White; Aude Chefdeville; Pedro Negrao de Assis; Song Cai; Vicki J Swier; Shreya S Bellampalli; Marissa D Giunta; Benjamin W Darbro; Dawn E Quelle; Jessica C Sieren; Margaret R Wallace; Christopher S Rogers; David K Meyerholz; Jill M Weimer
Journal:  Pain       Date:  2019-11       Impact factor: 7.926

2.  A Conserved Circadian Function for the Neurofibromatosis 1 Gene.

Authors:  Lei Bai; Yool Lee; Cynthia T Hsu; Julie A Williams; Daniel Cavanaugh; Xiangzhong Zheng; Carly Stein; Paula Haynes; Han Wang; David H Gutmann; Amita Sehgal
Journal:  Cell Rep       Date:  2018-03-27       Impact factor: 9.423

3.  Abnormal circadian oscillation of hippocampal MAPK activity and power spectrums in NF1 mutant mice.

Authors:  Lei Chen; Tatiana Serdyuk; Beimeng Yang; Shuai Wang; Shiqing Chen; Xixia Chu; Xu Zhang; Jinjing Song; Hechen Bao; Chengbin Zhou; Xiang Wang; Shuangle Dong; Lulu Song; Fujun Chen; Guang He; Lin He; Ying Zhou; Weidong Li
Journal:  Mol Brain       Date:  2017-07-03       Impact factor: 4.041

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.